KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Non-Current Assets (2016 - 2025)

Vertex Pharmaceuticals has reported Non-Current Assets over the past 17 years, most recently at $14.4 billion for Q4 2025.

  • Quarterly results put Non-Current Assets at $14.4 billion for Q4 2025, up 11.64% from a year ago — trailing twelve months through Dec 2025 was $55.2 billion (up 17.0% YoY), and the annual figure for FY2025 was $14.4 billion, up 11.64%.
  • Non-Current Assets for Q4 2025 was $14.4 billion at Vertex Pharmaceuticals, up from $14.3 billion in the prior quarter.
  • Over the last five years, Non-Current Assets for VRTX hit a ceiling of $14.4 billion in Q4 2025 and a floor of $3.6 billion in Q1 2021.
  • Median Non-Current Assets over the past 5 years was $6.8 billion (2023), compared with a mean of $8.1 billion.
  • Biggest five-year swings in Non-Current Assets: dropped 2.0% in 2021 and later soared 76.89% in 2024.
  • Vertex Pharmaceuticals' Non-Current Assets stood at $3.9 billion in 2021, then increased by 26.97% to $4.9 billion in 2022, then surged by 74.65% to $8.6 billion in 2023, then skyrocketed by 50.67% to $12.9 billion in 2024, then increased by 11.64% to $14.4 billion in 2025.
  • The last three reported values for Non-Current Assets were $14.4 billion (Q4 2025), $14.3 billion (Q3 2025), and $13.6 billion (Q2 2025) per Business Quant data.